Cargando…
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience
BACKGROUND: Neuromyelitis optica (NMO) is an inflammatory demyelinating central nervous system disease, with recurrent attacks of severe bilateral optic neuritis and longitudinally extensive transverse myelitis. Aggressive immunosuppression is essential to prevent clinical relapses and permanent dis...
Autores principales: | Jade, Jui Dilip, Bansi, Srishti, Singhal, Bhim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586117/ https://www.ncbi.nlm.nih.gov/pubmed/28904454 http://dx.doi.org/10.4103/aian.AIAN_499_16 |
Ejemplares similares
-
Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
por: Unni, Narayanan, et al.
Publicado: (2013) -
A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort
por: Barhate, Kavita Sohan, et al.
Publicado: (2014) -
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016) -
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018) -
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)